Keymed Biosciences Inc
Company Profile
Business description
Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house discovery and development of biological therapies that address large underserved medical needs in the autoimmune and oncology therapeutic areas. Its clinical-stage drug candidates include CM310, CM326, CM313, and CM336 among others. The company is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment. Geographically, it generates a majority of its revenue from overseas markets and the rest from Mainland China.
Contact
No. 18 BioTown Middle Road
Building D2
Tianfu International BioTown, Chengdu
Sichuan610219
CHNT: +86 2888610620
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
1,258
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,830.10 | 52.20 | 0.59% |
| CAC 40 | 7,878.46 | 111.75 | 1.44% |
| DAX 40 | 24,549.56 | 342.65 | 1.42% |
| Dow JONES (US) | 44,458.30 | 217.54 | 0.49% |
| FTSE 100 | 8,867.02 | 12.84 | 0.15% |
| HKSE | 23,947.51 | 55.19 | 0.23% |
| NASDAQ | 20,611.34 | 192.87 | 0.94% |
| Nikkei 225 | 39,553.17 | 268.11 | -0.67% |
| NZX 50 Index | 12,760.20 | 8.41 | -0.07% |
| S&P 500 | 6,263.26 | 37.74 | 0.61% |
| S&P/ASX 200 | 8,591.90 | 53.30 | 0.62% |
| SSE Composite Index | 3,512.02 | 18.97 | 0.54% |